Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetic studies of tacrolimus in transplant patients

Trial Profile

Pharmacokinetic studies of tacrolimus in transplant patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection; Renal transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Mar 2018 Results of analysis comparing simulated PK profiles with observed PK data to evaluate the influence of CYP3A4 abundance, hematocrit, serum albumin and creatinine levels on PK variability observed in renal transplant patients presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 24 Mar 2018 Results (n=35) assessing relationship between patient genotype and dose normalized PK parameters presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 28 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top